Asset Details
Do you wish to reserve the book?
Overcoming T790M mutant small cell lung cancer with the third‐generation EGFR‐TKI osimertinib
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Overcoming T790M mutant small cell lung cancer with the third‐generation EGFR‐TKI osimertinib
Do you wish to request the book?
Overcoming T790M mutant small cell lung cancer with the third‐generation EGFR‐TKI osimertinib
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Overcoming T790M mutant small cell lung cancer with the third‐generation EGFR‐TKI osimertinib
2019
Overview
A large number of EGFR mutant non‐small cell lung cancer patients primordially benefit from first‐line treatment with first‐generation EGFR‐tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib. However, multiple acquired resistance mechanisms have been described that limit the clinical efficacy of first‐generation EGFR‐TKIs. Herein, we report a rare case of lung adenocarcinoma harboring an EGFR exon 19‐deletion mutation before the administration of target therapy. This patient acquired resistance to first‐generation EGFR‐TKIs through small cell lung cancer (SCLC) transformation accompanied by the T790M mutation. Unexpectedly, this SCLC patient maintained a sensitive response to the third‐generation EGFR‐TKI osimertinib. This special case may indicate that osimertinib represents an effective target drug for SCLC patients who harbor an EGFR T790M mutation.
Publisher
John Wiley & Sons Australia, Ltd,John Wiley & Sons, Inc,Wiley
Subject
/ Adenocarcinoma of Lung - drug therapy
/ Adenocarcinoma of Lung - genetics
/ Adenocarcinoma of Lung - pathology
/ Aniline Compounds - therapeutic use
/ Drug Resistance, Neoplasm - genetics
/ EGFR
/ Female
/ Humans
/ Kinases
/ Lung Neoplasms - drug therapy
/ Mutation
/ NSCLC
/ Patients
/ Protein Kinase Inhibitors - therapeutic use
/ SCLC
/ Small Cell Lung Carcinoma - drug therapy
/ Small Cell Lung Carcinoma - genetics
